Introduction {#Sec1}
============

The human epidermal growth factor receptor 2 (HER2/neu, erbB2) constitutes, together with HER1 (EGFR, erbB1), HER3 (erbB3), and HER4 (erbB4), the type I group of 20 families of receptor tyrosine kinases. HER2 is a transmembrane 185 kDa protein; its encoding gene is on chromosome 17q21 \[[@CR1]\]. The orphan HER2 without known ligand acts as co-receptor for heterodimer formations with the other EGFR family members \[[@CR2]\]. These receptor heterodimers are drivers of cellular proliferation \[[@CR3]\], inhibit apoptosis \[[@CR4]\], and promote angiogenesis \[[@CR5]\].

HER2 overexpression characterizes particularly aggressive cancer types of various origin that share poor outcome \[[@CR6]\]. Originally detected in a subset of breast cancer \[[@CR7]\], amplification of the HER2 gene is the primary mechanism for protein overexpression \[[@CR8]\]. At present, targeted anti-HER2 therapies are established clinical routine for HER2 overexpressing/amplified carcinomas of the breast \[[@CR9]\] and stomach \[[@CR10]\]. Recent works have evaluated HER2 status in urothelial bladder cancer (UBC) in order to assess the therapeutic potential of this target, demonstrating significant protein overexpression (score 2+ or 3+) or gene amplification in approximately 10 % of the tumors \[[@CR11]--[@CR15]\]. In addition, several phase II and even phase III trials are currently investigating the possible benefit of HER2 targeted therapies for patients with UBC ([http://clinicaltrials.gov](http://clinicaltrials.gov/): NCT00151034, NCT00004856, NCT00005831. [https://www.clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/): EudraCT: 2007-001826-28).

Considering these developments, pathologists will presumably have to identify UBC with *HER2* amplification for personalized treatment in the nearer future. As only little is known about the histomorphology of these cases, better knowledge hereof might facilitate their identification. Morphological preselection before accomplishing additional examinations by immunohistochemistry or molecular procedures may even be interesting from an economical point of view. Finally, HER2 expression of amplified UBC has not been described in detail and the presence of additional mutations is largely unknown. We evaluated these open questions in a high-risk cohort of advanced metastasizing UBC.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Our cohort comprised of 150 bladder cancer patients (29 females and 121 males) treated by standardized, extended bilateral pelvic lymphadenectomy with cystectomy as a single procedure at the Department of Urology, University Hospital of Bern, Switzerland. No neoadjuvant therapy was given. Median age at surgery was 67 years (range 35--89); most primary tumors were advanced (pT1, *n* = 4; pT2, *n* = 17; pT3, *n* = 92; and pT4, *n* = 37).

Pathological techniques {#Sec4}
-----------------------

The opened bladder specimens were fixed overnight in neutral buffered formalin and processed at the Institute of Pathology, University of Bern. The tumor samples tested for molecular alterations were collected in accordance with the required international ethical guidelines including approval by the Institutional Review Board at the Institute of Pathology, University of Bern.

Identification of HER2 amplified and non-amplified cancers {#Sec5}
----------------------------------------------------------

A TMA with the 150 UBC was constructed and evaluated for *HER2* amplification by fluorescence in situ hybridization. These results were published previously \[[@CR12]\]. In the current study, the 13 amplified tumors (HER2/CEP17 ratio ≥ 2.2 \[[@CR16]\]) were further investigated and their histopathological characteristics compared with 13 non-amplified UBC (HER2/CEP17 ratio \< 1.8; \[[@CR16]\]) from our cohort, matched by age, pT stage, and operation date.

Morphological evaluation {#Sec6}
------------------------

All *HER2* amplified and non-amplified urothelial carcinomas were evaluated by two independent investigators (JT and AF) for numbers and percentage of histomorphological variants \[[@CR17]\] present in the tumors and the final result was formulated as a consensus. These numbers and percentages in each subgroup were added up for comparison. The amount of tumor-associated inflammation was graded from a score zero to three (negative, mild, moderate, and strong) for each case based on the spectrum observed over all tumors.

Immunohistochemistry and in situ hybridization {#Sec7}
----------------------------------------------

Immunohistochemistry for the detection of HER2 expression was performed on one representative cross sectional slide per tumor, displaying a maximum of tumor tissue mass. The original HercepTest (DAKO, Glostrup Denmark) was used for immunohistochemical stains which were performed according to the manufacturer's protocol. HER2 protein expression per cross sectional slide was classified according to the modified DAKO criteria \[[@CR16]\]: negative (0/1+), weakly positive (2+), and positive (3+) with a cut-off for score 3+ for a more than 30 % strong complete membranous staining of the tumor cells.

For comparison of Her2 protein phenotype and amplification status, dual in situ hybridization (ISH) was performed on one large section. The *HER2* gene is detected by a dinitrophenyl (DNP) labeled probe and visualized utilizing VENTANA *ultra*View Silver ISH DNP (black signals) Detection. The chromosome 17 centromere is targeted with a digoxigenin (DIG) labeled probe and detected using VENTANA *ultra*View Red ISH DIG detection (red signals). Detailed instructions for hybridization procedures are provided by the manufacturer.

*HER2* mutation analysis {#Sec8}
------------------------

Genomic DNA was obtained from all amplified tumor tissues by overnight digestion with proteinase K at 55 °C followed by DNA extraction using the BioRobot EZ1 workstation (Qiagen). Intron-based primers were used to amplify exon 19 and 20 encompassing the main hot spot of activating mutations of the *HER2* gene \[[@CR18], [@CR19]\]. The primer sequences were as follows: forward primer exon 19, 5′-CCCACGCTCTTCTCACTCAT-3′; reverse primer exon 19; 5′-TCCTTCCTGTCCTCCTAGCA-3′; forward primer exon 20, 5′-TGGTCTCCCATACCCTCTCA-3′; and reverse primer exon 20, 5′-CAAAGAGCCCAGGTGCATA-3′. Sequence analysis was performed using the 3500 genetic analyzer (Applied Biosystems). In addition, exon 20 was analyzed for in-frame-insertions by capillary electrophoresis using a 6-carboxy-fluorescine labeled forward primer and the same reverse primer.

Results {#Sec9}
=======

Morphological features of HER2 amplified and non-amplified urothelial bladder cancer {#Sec10}
------------------------------------------------------------------------------------

A hallmark of the *HER2* amplified tumor group was micropapillary growth, which was present in 10 out of 13 cases (77 %): three tumors (23 %) were purely (100 %), one tumor (8 %) extensively (80 %), and six tumors (46 %) focally (up to 10 %) micropapillary. When related to the entire tumor mass within the *HER2* amplified group, the micropapillary proportion accounted for 32.7 % of this tumor mass (Figs. [1a, b](#Fig1){ref-type="fig"} and [3](#Fig3){ref-type="fig"}). *HER2* amplified tumors often presented with components of UBC variants (median 2 per tumor) including the nested variant (Fig. [1c](#Fig1){ref-type="fig"}), two tumors (15 %) were composed of three different components. Finally, tumor-associated inflammation was high (mean score 1.9) and showed both intratumoral and peritumoral infiltrates (Fig. [1d](#Fig1){ref-type="fig"}).Fig. 1*HER2* amplified urothelial bladder cancers often show micropapillary morphology (**a**, **b** HE × 10 and × 40) throughout the tumor or together with other components like the nested variant (**c** HE × 20). *HER2* amplified urothelial bladder cancer often presents with marked tumor-associated chronic inflammation (**d** HE × 20)Fig. 2*HER2* non-amplified urothelial bladder cancers mostly show conventional solid morphology (**a** HE × 10); **b** sarcomatoid variant (HE × 20)Fig. 3Comparison of *HER2* amplified and non-amplified urothelial bladder cancers (*n*=13 each) in regard to their morphology (the tumor components are given as percentage in relation to the total tumor mass in each group): micropapillary architecture is a key feature of *HER2* amplified urothelial bladder cancer

In contrast, the *HER2* non-amplified group showed mostly conventional UBC: nine tumors (69 %) were purely (100 %) and three tumors (23 %) were extensively (60--70 %) of this type (Fig. [2a](#Fig2){ref-type="fig"}). One tumor (8 %) featured a purely sarcomatoid growth pattern (100 %, Fig. [2b](#Fig2){ref-type="fig"}) with accompanying urothelial carcinoma in situ and one (8 %) had micropapillary components (40 % of the otherwise conventional UBC), which accounted for 3 % of the total tumor mass in this group. Moreover, tumor-associated inflammation (mean score 1.2) was scarce compared to the amplified group. The trend for more monophasic growth in *HER2* non-amplified compared to *HER2* amplified tumors was reflected in a lower median number of morphologically different tumor components per tumor (1 vs. 2 in the *HER2* amplified group) and the absence of tumors with more than two components.

Immunohistochemistry and ISH of HER2 amplified UBC {#Sec11}
--------------------------------------------------

Ten out of the thirteen *HER2* amplified tumors (77 %) were scored as strongly HER2 positive (3 +), out of which six tumors (46 %) resulted in 100 %, two tumors (15 %) in 95 %, one tumor (8 %) in 60 %, and one tumor (8 %) in 50 % strong and complete membranous staining (Fig. [4a, b](#Fig4){ref-type="fig"}). Interestingly, we infrequently noted a mosaic HER2 expression pattern within overall HER2 expressing tumors scored as 3+ (Fig. [3](#Fig3){ref-type="fig"}). Positive cells were found adjacent to negative or incompletely stained cells in alternating patterns (Fig. [4c](#Fig4){ref-type="fig"}). No differences in staining intensities were noted between morphological diverse components and also not between superficial and deep parts of these tumors.Fig. 4HER2 immunohistochemistry: **a** strong membranous positivity in 100 % of the tumor cells of a conventional urothelial bladder cancer, score 3+; **b** score 3+ in a micropapillary variant; **c** mosaic pattern, score 3+; **d** strong positivity in carcinoma in situ, negativity in the adjacent normal urothelium

There were no HER2 2+ but three (23 %) HER2 negative tumors: one case (8 %) was scored as 1+ with a 50 % weak, incomplete membranous staining and two score 0 cases (15 %) with incomplete weak membranous immunohistochemical reaction in less than 10 % of the tumor cells.

Two cases comprised areas of carcinoma in situ where we noted a strong immunohistochemical reaction throughout the lesion (Fig. [4d](#Fig4){ref-type="fig"}).

We reassessed the relation of HER2 protein overexpression and amplification status on two consecutive large sections. The immunostain showed 100 % strongly positive neoplastic cells (score 3+) and the dual ISH stain presented *HER2* amplification in all cancer cells (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5In situ hybridization showing Her2 amplification in 100 % of the neoplastic urothelial bladder cancer cells (*HER2* gene = *black*, centromere 17 = *red*)

HER2 mutation analysis {#Sec12}
----------------------

The exons 19 and 20 of the *HER2* gene were sequenced in all *HER2* amplified and non-amplified tumors to assess if some of them contain activating mutations within these regions. None of the tumors contained a mutation in exon 20. However, one *HER2* amplified tumor harbored a D769N mutation (c.2305G \> A) in exon 19 (Fig. [6](#Fig6){ref-type="fig"}). This mutation is located in the αC helix of the catalytic domain of the enzyme.Fig. 6D769N (c.2305G \> A) mutation in Exon 19 of the *HER2* gene

Discussion {#Sec13}
==========

Specific genetic alterations in cancers may be associated with particular morphological features as shown in colon and prostate cancer \[[@CR20], [@CR21]\]. In UBC, there is currently only one comparable investigation. Ching et al. \[[@CR22]\] evaluated the particularly aggressive micropapillary variant of urothelial carcinoma for HER2 aberrations \[[@CR22]\] and demonstrated HER2 protein overexpression (score 2+ or 3+) in 68 % and *HER2* gene amplification in 42 % of their 20 tumors. However, the micropapillary variant with a prevalence of 0.6--6 % is rare in UBC \[[@CR17], [@CR22], [@CR23]\], and in general, a component of a conventional UBC. As yet, the morphological spectrum of UBC with *HER2* amplification, which is an aggressive and from a therapeutic point of view a potentially distinct subgroup, has not been described. Better knowledge about its morphology might help to better identify these tumors. Therefore, we first identified *HER2* amplified UBC in our cohort of high-risk, metastasizing tumors and subsequently described their morphology and HER2 expression patterns.

Micropapillary tumor growth was present in 77 % of our *HER2* amplified tumors; 31 % were purely or predominantly micropapillary UBC, the residual tumors had minor micropapillary fractions. The proportion of micropapillary growth in relation to the entire tumor mass in this group was 33 %. This contrasts significantly with the *HER2* non-amplified UBC group, in which micropapillary growth was present in only one tumor and this component occupied just 3 % of the entire evaluated tumor mass in this group. In addition, the *HER2* amplified tumors presented with a significantly higher morphological heterogeneity than the control group, reflected by a higher number of subtype components per tumor, and showed a significantly higher tumor-associated chronic inflammatory infiltrate. Interestingly, the latter is in line with a recent study showing that HER2 overexpression activates multiple inflammatory pathways, especially NF-κB, which is critical to Interleukin-6 (Il-6) expression \[[@CR24]\]. Whether or not a relationship exists with the more recently described association of polyoma virus with micropapillary UBC needs further investigation \[[@CR25], [@CR26]\]. Taken together, these histomorphological features of *HER2* amplified UBC---frequent micropapillary architecture, morphological heterogeneity and marked tumor-associated chronic inflammation---allow pathologists to better identify this clinically important, particularly aggressive subset of UBC \[[@CR12]\] and herewith to contribute to enhanced survival prediction and preselection for potential anti-HER2 therapies in the future.

Only few studies have investigated *HER2* amplification and overexpression simultaneously in all their bladder cancer patients \[[@CR27]--[@CR29]\]. However, they only categorized the tumors according to DAKO scores and did not report the exact percentage and distribution of positive tumor cells. We noted a strong complete membranous immunoreactivity for HER2 in 77 % of our *HER2* amplified tumors. Importantly, most of these tumors showed this staining in virtually all neoplastic cells; only two cases had a partial tumor staining of 60 and 50 % of the tumor cells. This suggests that HER2 overexpression mostly occurs as an early event in tumorigenesis and only rarely in subsequent tumor development. Further evidence for early HER2 overexpression in tumorigenesis was noted in the two patients with residual urothelial carcinoma in situ which were strongly HER2 positive (score 3+). Interestingly, even though our *HER2* amplified group presented with marked heterogeneous morphology, this observation was not reflected in the HER2 expression pattern. There was no HER2 expression difference between the morphologically diverse components of these tumors; in particular, the micropapillary areas did not show a more pronounced immunoreactivity than the other histological components. Notably, 23 % of our *HER2* amplified tumors were immunohistochemically HER2 negative. Similarly, high rates of "false negative" UBC (20--24 %) have been reported by others \[[@CR30], [@CR29]\] and were attributed to putative fixation artifacts. Therefore, we specifically investigated HER2 expression intensity along the gradient of diffusion of formalin from the superficial bladder wall to deeper parts. However, there were no increments in staining intensities to be found.

Finally, we tested all UBC for activating *HER2* mutations which have been reported in a small subset of lung and breast cancer \[[@CR19], [@CR31], [@CR32]\]. Interestingly, we detected a D769N mutation in a *HER2* amplified tumor sample. To our knowledge, this mutation has not been described so far, also not in the series of Ross et al who tested 15 micropapillary UBC for mutations \[[@CR33]\]. However, two mutations, D769H and D769Y, occurring at the same amino acid position were described in breast cancer \[[@CR31]\]. Both mutations conferred constitutive activity of the HER2 kinase. Cell lines bearing these mutations revealed increased HER2, EGFR, and PLCγ phosphorylation and had more rapid tumor growth in xenograft models compared to the wild type control. In addition, both mutations conferred sensitivity to the HER2 inhibitor lapatinib \[[@CR31]\]. The authors suggested that activation of HER2 by these mutations may be due to loss of the acidic side chain at D769, or alternatively, due to an aromatic ring introduced by histidine or tyrosine, respectively. Asparagine and tyrosine can often been substituted without affecting protein function since both amino acids contain uncharged polar side chains. If D769N mutation, like D769Y mutation, induces HER2 activity, has to be confirmed experimentally.

In conclusion, the aggressive *HER2* amplified subtype of UBC shows specific histomorphological features---frequent micropapillary architecture, morphological heterogeneity, and marked tumor-associated chronic inflammation---that may allow identifying them with high accuracy. Approximately three-quarters of these tumors overexpress HER2 strongly. This is promising for targeted anti-HER2 therapies.
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